VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration aimed at developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate that combines the companies' technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide. This finding supports the potential of the approach to selectively deliver therapeutic oligonucleotides to disease-specific cells, a key objective for improving treatment efficacy and reducing side effects.
The companies stated that they are currently discussing next steps in the collaboration. VERAXA noted that these results demonstrate the potential application of its proprietary click chemistry-powered conjugation technology beyond its primary focus on solid tumors. This expansion into immune diseases could broaden the therapeutic reach of VERAXA's platform, which is already being developed for bispecific T cell engagers, bispecific antibody-drug conjugates (ADCs), and other innovative formats.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, guided by rigorous quality-by-design principles. Its pipeline includes ADCs and proprietary BiTAC formats, which are advancing into clinical development and beyond.
The collaboration with Secarna, a company specializing in antisense oligonucleotide therapies, aims to combine VERAXA's conjugation technology with Secarna's expertise in oligonucleotide design. The early success in enhancing potency suggests that the AOC approach could offer a more targeted and effective treatment option for chronic immune conditions, where current therapies often lack specificity and cause systemic side effects.
Secarna Pharmaceuticals is a privately held company focused on developing novel antisense oligonucleotide therapies for a range of diseases. The partnership with VERAXA is part of Secarna's strategy to leverage its proprietary Antisense Oligonucleotide Platform to create new therapeutic modalities. The positive early results are a significant milestone for both companies, as they validate the scientific rationale behind the collaboration and pave the way for further development.
For VERAXA, these findings could also have implications for its broader pipeline, as the technology may be applicable to other diseases beyond oncology. The company's newsroom provides updates on its latest developments, and investors can access more information at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/IF9Cy.
The announcement underscores the growing interest in AOCs as a novel class of therapeutics that can combine the targeting capabilities of antibodies with the gene-regulating properties of oligonucleotides. If successful, this approach could lead to more precise treatments for autoimmune diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease, potentially improving patient outcomes and quality of life.
As the collaboration progresses, further studies will be needed to confirm the in vitro results and move toward clinical development. The companies have not provided a timeline for next steps, but the positive early data are encouraging for the field and for investors watching the development of this emerging therapeutic modality.
